Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing

The healthcare sector is outperforming the broader market and tech sector in Q4, confirming a substantial capital shift into the defensive industry.

MarketBeat

Amgen Stock: New All-Time Highs Ahead After Earnings Beat

Amgen stock jumps after a strong beat-and-raise quarter, pushing shares near split-adjusted all-time highs and signaling more upside ahead

MarketBeat

Marjorie Taylor Greene Already Made Double-Digit Gains From Amazon; Cardinal Health Trades Days Before Earnings Beat

Greene's investments in Amazon and Cardinal Health on 24 October are up 11.5% and 21.5%, respectively, following the companies' strong Q3 earnings reports.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Amgen Stock: Analyst Estimates & Ratings

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.

Barchart

The Saturday Spread: Using Data Science to Find Call Spreads Priced in Your Favor

It’s already difficult enough when you step into the world of options. Here’s how to even up the odds against the big dogs.

Barchart

Here's What to Expect From Amgen’s Next Earnings Report

Amgen is scheduled to report its third-quarter earnings next month, and analysts forecast a modest single-digit decline in profits.

Barchart

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

The Saturday Spread: 3 Beaten-Down Stocks Making a Statistical Case for a Comeback

Here’s an innovative approach to deciphering which red-stained stocks are actually worth a look for bullish contrarians.

Barchart

Amgen Expands US Manufacturing Network Amid New Tariff Policy

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Benzinga

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga

EMA Backs Amgen Drug For Rare Autoimmune Disorder

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).

Benzinga

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

Benzinga

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Stock Index Futures Gain on Strong Earnings and Fed Rate-Cut Bets

September S&P 500 E-Mini futures (ESU25) are up +0.24%, and September Nasdaq 100 E-Mini futures (NQU25) are up +0.30% this morning, extending a rebound driven by bets on Federal Reserve interest rate cuts and solid corporate earnings.

Barchart

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Benzinga

AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and efficacy of gefurulimab in adults with generalized myasthenia gravis (gMG). The trial enrolled 260 patients.

Kiplinger

Dow Leads as Merck, Amgen Gain: Stock Market Today

Second-quarter earnings season remained top of mind Tuesday, with Coca-Cola and GM among those reporting.

Barchart

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Benzinga

Honeywell, Caterpillar, Freeport-McMoRan And A Health Care Stock On CNBC's 'Final Trades'

As Wall Street looks ahead to the July 4 holiday weekend, a wave of optimism ripples through the trading floor, with seasoned investors poised to capitalize on emerging opportunities.

AAP

Career blocks for female scientists put under scrutiny

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of mentorship, funding and job security.

1 2 3 4 5

People

Marjorie Taylor Greene

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.